Research programme: allergy therapy - Infinity Pharmaceuticals/Kyorin

Drug Profile

Research programme: allergy therapy - Infinity Pharmaceuticals/Kyorin

Alternative Names: Allergy therapy research programme - Infinity Pharmaceuticals/Kyorin

Latest Information Update: 07 Dec 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Infinity Pharmaceuticals; Kyorin Pharmaceutical
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypersensitivity

Most Recent Events

  • 26 Sep 2006 No development reported - Preclinical for Allergy in USA (unspecified route)
  • 13 Sep 2006 Discovery Partners International has been acquired and merged into Infinity Pharmaceuticals
  • 09 Sep 2003 Preclinical trials in Allergy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top